An excerpt of the letter follows: In this letter, we highlight three areas where we are particularly isappointed with the Company: 1) The disconnect between James Mullen's compensation and Biogen Idec's stock performance; 2) The lack of a consistent commitment to return cash to shareholders; and 3) The Company's excessive and fruitless Research and Development spend. We ask the Board to take swift action to remedy our concerns, which we believe will result in an immediate and meaningful creation of shareholder value. :theflyonthewall.com
News For BIIB From The Last 14 Days
Check below for free stories on BIIB the last two weeks.
There are 15 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing.
FDA says 31 cases of PML infections linked to Tysabri, Bloomberg reports
Tysabri will carry new safety information, Bloomberg reports. The FDA says that Tysabri's benefits continue to outweigh the risks and the agency advises doctors to monitor patients for immune syndrome. :theflyonthewall.com